Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors (Q44471523)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors |
scientific article |
Statements
1 reference
Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors (English)
1 reference
Luca Gianni
1 reference
Adrian Harris
1 reference
Roy S Herbst
1 reference
Patricia M LoRusso
1 reference
Danny Rischin
1 reference
Malcolm Ranson
1 reference
Hilary Calvert
1 reference
Eric Raymond
1 reference
Dirk Kieback
1 reference
Stan Kaye
1 reference
Thomas Bjork
1 reference
Anne-Marie Maddox
1 reference
Mace L Rothenberg
1 reference
Eric J Small
1 reference
Eric H Rubin
1 reference
Andrea Feyereislova
1 reference
Anne Heyes
1 reference
Steven D Averbuch
1 reference
Judith Ochs
1 reference
José Baselga
1 reference
1 June 2003
1 reference
1 reference
9
1 reference
6
1 reference
2040-2048
1 reference
Identifiers
1 reference